INTERCEPT PHARMACEUTICALS, INC. Insider Trading for March 2015
FREE EMAIL WATCHDOG
Get free email notifications about insider trading in INTERCEPT PHARMACEUTICALS, INC..
- Your email is safe with us.
- The service is free and you can unsubscribe at any time.
General | Insiders | Insider Transactions | Monthly Overview | Weekly Overview
Overview of insider trading in INTERCEPT PHARMACEUTICALS, INC. for March 2015.
| Date | Ticker | Company | Owner | Relationship | Transaction | Code | Cost ($) | Shares | Transaction Value ($) | Total Shares | % Holdings |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Mar 30 2015 | ICPT | INTERCEPT PHARMACE ... | SILVERSTEIN JONATHAN | Director | Sell | S | 294.82 | 90 | 26,534 | 1,120,324 | 1.1 M to 1.1 M (-0.01 %) |
| Mar 30 2015 | ICPT | INTERCEPT PHARMACE ... | SILVERSTEIN JONATHAN | Director | Sell | S | 293.85 | 2,500 | 734,625 | 1,120,414 | 1.1 M to 1.1 M (-0.22 %) |
| Mar 30 2015 | ICPT | INTERCEPT PHARMACE ... | SILVERSTEIN JONATHAN | Director | Sell | S | 292.13 | 6,000 | 1,752,780 | 1,122,914 | 1.1 M to 1.1 M (-0.53 %) |
| Mar 30 2015 | ICPT | INTERCEPT PHARMACE ... | SILVERSTEIN JONATHAN | Director | Sell | S | 291.12 | 3,700 | 1,077,144 | 1,128,914 | 1.1 M to 1.1 M (-0.33 %) |
| Mar 30 2015 | ICPT | INTERCEPT PHARMACE ... | SILVERSTEIN JONATHAN | Director | Sell | S | 290.02 | 13,974 | 4,052,739 | 1,132,614 | 1.1 M to 1.1 M (-1.22 %) |
| Mar 30 2015 | ICPT | INTERCEPT PHARMACE ... | SILVERSTEIN JONATHAN | Director | Sell | S | 289.07 | 15,131 | 4,373,918 | 1,146,588 | 1.2 M to 1.1 M (-1.30 %) |
| Mar 30 2015 | ICPT | INTERCEPT PHARMACE ... | SILVERSTEIN JONATHAN | Director | Sell | S | 288.11 | 26,028 | 7,498,927 | 1,161,719 | 1.2 M to 1.2 M (-2.19 %) |
| Mar 30 2015 | ICPT | INTERCEPT PHARMACE ... | SILVERSTEIN JONATHAN | Director | Sell | S | 287.16 | 18,041 | 5,180,654 | 1,187,747 | 1.2 M to 1.2 M (-1.50 %) |
| Mar 30 2015 | ICPT | INTERCEPT PHARMACE ... | SILVERSTEIN JONATHAN | Director | Sell | S | 286.24 | 7,611 | 2,178,573 | 1,205,788 | 1.2 M to 1.2 M (-0.63 %) |
| Mar 30 2015 | ICPT | INTERCEPT PHARMACE ... | SILVERSTEIN JONATHAN | Director | Sell | S | 285.18 | 23,903 | 6,816,658 | 1,213,399 | 1.2 M to 1.2 M (-1.93 %) |
| Mar 30 2015 | ICPT | INTERCEPT PHARMACE ... | SILVERSTEIN JONATHAN | Director | Sell | S | 284.20 | 16,845 | 4,787,349 | 1,237,302 | 1.3 M to 1.2 M (-1.34 %) |
| Mar 30 2015 | ICPT | INTERCEPT PHARMACE ... | SILVERSTEIN JONATHAN | Director | Sell | S | 282.87 | 9,357 | 2,646,815 | 1,254,147 | 1.3 M to 1.3 M (-0.74 %) |
| Mar 30 2015 | ICPT | INTERCEPT PHARMACE ... | SILVERSTEIN JONATHAN | Director | Sell | S | 282.13 | 8,397 | 2,369,046 | 1,263,504 | 1.3 M to 1.3 M (-0.66 %) |
| Mar 30 2015 | ICPT | INTERCEPT PHARMACE ... | SILVERSTEIN JONATHAN | Director | Sell | S | 281.11 | 5,623 | 1,580,682 | 1,271,901 | 1.3 M to 1.3 M (-0.44 %) |
| Mar 30 2015 | ICPT | INTERCEPT PHARMACE ... | ORBIMED ADVISORS LLC | Director | Sell | S | 294.82 | 90 | 26,534 | 1,120,324 | 1.1 M to 1.1 M (-0.01 %) |
| Mar 30 2015 | ICPT | INTERCEPT PHARMACE ... | ORBIMED ADVISORS LLC | Director | Sell | S | 293.85 | 2,500 | 734,625 | 1,120,414 | 1.1 M to 1.1 M (-0.22 %) |
| Mar 30 2015 | ICPT | INTERCEPT PHARMACE ... | ORBIMED ADVISORS LLC | Director | Sell | S | 292.13 | 6,000 | 1,752,780 | 1,122,914 | 1.1 M to 1.1 M (-0.53 %) |
| Mar 30 2015 | ICPT | INTERCEPT PHARMACE ... | ORBIMED ADVISORS LLC | Director | Sell | S | 291.12 | 3,700 | 1,077,144 | 1,128,914 | 1.1 M to 1.1 M (-0.33 %) |
| Mar 30 2015 | ICPT | INTERCEPT PHARMACE ... | ORBIMED ADVISORS LLC | Director | Sell | S | 290.02 | 13,974 | 4,052,739 | 1,132,614 | 1.1 M to 1.1 M (-1.22 %) |
| Mar 30 2015 | ICPT | INTERCEPT PHARMACE ... | ORBIMED ADVISORS LLC | Director | Sell | S | 289.07 | 15,131 | 4,373,918 | 1,146,588 | 1.2 M to 1.1 M (-1.30 %) |
| Mar 30 2015 | ICPT | INTERCEPT PHARMACE ... | ORBIMED ADVISORS LLC | Director | Sell | S | 288.11 | 26,028 | 7,498,927 | 1,161,719 | 1.2 M to 1.2 M (-2.19 %) |
| Mar 30 2015 | ICPT | INTERCEPT PHARMACE ... | ORBIMED ADVISORS LLC | Director | Sell | S | 287.16 | 18,041 | 5,180,654 | 1,187,747 | 1.2 M to 1.2 M (-1.50 %) |
| Mar 30 2015 | ICPT | INTERCEPT PHARMACE ... | ORBIMED ADVISORS LLC | Director | Sell | S | 286.24 | 7,611 | 2,178,573 | 1,205,788 | 1.2 M to 1.2 M (-0.63 %) |
| Mar 30 2015 | ICPT | INTERCEPT PHARMACE ... | ORBIMED ADVISORS LLC | Director | Sell | S | 285.18 | 23,903 | 6,816,658 | 1,213,399 | 1.2 M to 1.2 M (-1.93 %) |
| Mar 30 2015 | ICPT | INTERCEPT PHARMACE ... | ORBIMED ADVISORS LLC | Director | Sell | S | 284.20 | 16,845 | 4,787,349 | 1,237,302 | 1.3 M to 1.2 M (-1.34 %) |
| Mar 30 2015 | ICPT | INTERCEPT PHARMACE ... | ORBIMED ADVISORS LLC | Director | Sell | S | 282.87 | 9,357 | 2,646,815 | 1,254,147 | 1.3 M to 1.3 M (-0.74 %) |
| Mar 30 2015 | ICPT | INTERCEPT PHARMACE ... | ORBIMED ADVISORS LLC | Director | Sell | S | 282.13 | 8,397 | 2,369,046 | 1,263,504 | 1.3 M to 1.3 M (-0.66 %) |
| Mar 30 2015 | ICPT | INTERCEPT PHARMACE ... | ORBIMED ADVISORS LLC | Director | Sell | S | 281.11 | 5,623 | 1,580,682 | 1,271,901 | 1.3 M to 1.3 M (-0.44 %) |
| Mar 25 2015 | ICPT | INTERCEPT PHARMACE ... | SILVERSTEIN JONATHAN | Director | Sell | S | 270.23 | 2,800 | 756,644 | 1,277,524 | 1.3 M to 1.3 M (-0.22 %) |
| Mar 25 2015 | ICPT | INTERCEPT PHARMACE ... | SILVERSTEIN JONATHAN | Director | Sell | S | 275.56 | 3,844 | 1,059,253 | 1,280,324 | 1.3 M to 1.3 M (-0.30 %) |
| Mar 25 2015 | ICPT | INTERCEPT PHARMACE ... | SILVERSTEIN JONATHAN | Director | Sell | S | 275.00 | 12,066 | 3,318,150 | 1,284,168 | 1.3 M to 1.3 M (-0.93 %) |
| Mar 25 2015 | ICPT | INTERCEPT PHARMACE ... | SILVERSTEIN JONATHAN | Director | Sell | S | 273.19 | 2,700 | 737,613 | 1,296,234 | 1.3 M to 1.3 M (-0.21 %) |
| Mar 25 2015 | ICPT | INTERCEPT PHARMACE ... | SILVERSTEIN JONATHAN | Director | Sell | S | 272.13 | 3,050 | 829,997 | 1,298,934 | 1.3 M to 1.3 M (-0.23 %) |
| Mar 25 2015 | ICPT | INTERCEPT PHARMACE ... | SILVERSTEIN JONATHAN | Director | Sell | S | 271.15 | 6,063 | 1,643,982 | 1,301,984 | 1.3 M to 1.3 M (-0.46 %) |
| Mar 25 2015 | ICPT | INTERCEPT PHARMACE ... | SILVERSTEIN JONATHAN | Director | Sell | S | 270.13 | 9,574 | 2,586,225 | 1,308,047 | 1.3 M to 1.3 M (-0.73 %) |
| Mar 25 2015 | ICPT | INTERCEPT PHARMACE ... | SILVERSTEIN JONATHAN | Director | Sell | S | 269.10 | 1,539 | 414,145 | 1,317,621 | 1.3 M to 1.3 M (-0.12 %) |
| Mar 25 2015 | ICPT | INTERCEPT PHARMACE ... | SILVERSTEIN JONATHAN | Director | Sell | S | 268.13 | 6,764 | 1,813,631 | 1,319,160 | 1.3 M to 1.3 M (-0.51 %) |
| Mar 25 2015 | ICPT | INTERCEPT PHARMACE ... | SILVERSTEIN JONATHAN | Director | Sell | S | 288.60 | 1,000 | 288,600 | 1,325,924 | 1.3 M to 1.3 M (-0.08 %) |
| Mar 25 2015 | ICPT | INTERCEPT PHARMACE ... | SILVERSTEIN JONATHAN | Director | Sell | S | 286.04 | 1,400 | 400,456 | 1,326,924 | 1.3 M to 1.3 M (-0.11 %) |
| Mar 25 2015 | ICPT | INTERCEPT PHARMACE ... | SILVERSTEIN JONATHAN | Director | Sell | S | 283.44 | 52 | 14,739 | 1,328,324 | 1.3 M to 1.3 M (0.00 %) |
| Mar 25 2015 | ICPT | INTERCEPT PHARMACE ... | SILVERSTEIN JONATHAN | Director | Sell | S | 283.29 | 1,548 | 438,533 | 1,328,376 | 1.3 M to 1.3 M (-0.12 %) |
| Mar 25 2015 | ICPT | INTERCEPT PHARMACE ... | SILVERSTEIN JONATHAN | Director | Sell | S | 282.00 | 3,500 | 987,000 | 1,329,924 | 1.3 M to 1.3 M (-0.26 %) |
| Mar 25 2015 | ICPT | INTERCEPT PHARMACE ... | SILVERSTEIN JONATHAN | Director | Sell | S | 281.01 | 6,306 | 1,772,049 | 1,333,424 | 1.3 M to 1.3 M (-0.47 %) |
| Mar 25 2015 | ICPT | INTERCEPT PHARMACE ... | SILVERSTEIN JONATHAN | Director | Sell | S | 280.00 | 9,465 | 2,650,200 | 1,339,730 | 1.3 M to 1.3 M (-0.70 %) |
| Mar 25 2015 | ICPT | INTERCEPT PHARMACE ... | SILVERSTEIN JONATHAN | Director | Sell | S | 279.00 | 3,668 | 1,023,372 | 1,349,195 | 1.4 M to 1.3 M (-0.27 %) |
| Mar 25 2015 | ICPT | INTERCEPT PHARMACE ... | SILVERSTEIN JONATHAN | Director | Sell | S | 278.00 | 14,152 | 3,934,256 | 1,352,863 | 1.4 M to 1.4 M (-1.04 %) |
| Mar 25 2015 | ICPT | INTERCEPT PHARMACE ... | SILVERSTEIN JONATHAN | Director | Sell | S | 276.96 | 8,195 | 2,269,687 | 1,367,015 | 1.4 M to 1.4 M (-0.60 %) |
| Mar 25 2015 | ICPT | INTERCEPT PHARMACE ... | SILVERSTEIN JONATHAN | Director | Sell | S | 275.95 | 37,666 | 10,393,933 | 1,375,210 | 1.4 M to 1.4 M (-2.67 %) |
| Mar 25 2015 | ICPT | INTERCEPT PHARMACE ... | SILVERSTEIN JONATHAN | Director | Sell | S | 274.86 | 3,579 | 983,724 | 1,412,876 | 1.4 M to 1.4 M (-0.25 %) |
| Mar 25 2015 | ICPT | INTERCEPT PHARMACE ... | SILVERSTEIN JONATHAN | Director | Sell | S | 273.89 | 11,869 | 3,250,800 | 1,416,455 | 1.4 M to 1.4 M (-0.83 %) |
| Mar 25 2015 | ICPT | INTERCEPT PHARMACE ... | SILVERSTEIN JONATHAN | Director | Sell | S | 272.79 | 8,638 | 2,356,360 | 1,428,324 | 1.4 M to 1.4 M (-0.60 %) |
| Mar 25 2015 | ICPT | INTERCEPT PHARMACE ... | SILVERSTEIN JONATHAN | Director | Sell | S | 271.70 | 7,764 | 2,109,479 | 1,436,962 | 1.4 M to 1.4 M (-0.54 %) |
| Mar 25 2015 | ICPT | INTERCEPT PHARMACE ... | SILVERSTEIN JONATHAN | Director | Sell | S | 270.70 | 40,598 | 10,989,879 | 1,444,726 | 1.5 M to 1.4 M (-2.73 %) |
| Mar 25 2015 | ICPT | INTERCEPT PHARMACE ... | ORBIMED ADVISORS LLC | Director | Sell | S | 270.23 | 2,800 | 756,644 | 1,277,524 | 1.3 M to 1.3 M (-0.22 %) |
| Mar 25 2015 | ICPT | INTERCEPT PHARMACE ... | ORBIMED ADVISORS LLC | Director | Sell | S | 275.56 | 3,844 | 1,059,253 | 1,280,324 | 1.3 M to 1.3 M (-0.30 %) |
| Mar 25 2015 | ICPT | INTERCEPT PHARMACE ... | ORBIMED ADVISORS LLC | Director | Sell | S | 275.00 | 12,066 | 3,318,150 | 1,284,168 | 1.3 M to 1.3 M (-0.93 %) |
| Mar 25 2015 | ICPT | INTERCEPT PHARMACE ... | ORBIMED ADVISORS LLC | Director | Sell | S | 273.19 | 2,700 | 737,613 | 1,296,234 | 1.3 M to 1.3 M (-0.21 %) |
| Mar 25 2015 | ICPT | INTERCEPT PHARMACE ... | ORBIMED ADVISORS LLC | Director | Sell | S | 272.13 | 3,050 | 829,997 | 1,298,934 | 1.3 M to 1.3 M (-0.23 %) |
| Mar 25 2015 | ICPT | INTERCEPT PHARMACE ... | ORBIMED ADVISORS LLC | Director | Sell | S | 271.15 | 6,063 | 1,643,982 | 1,301,984 | 1.3 M to 1.3 M (-0.46 %) |
| Mar 25 2015 | ICPT | INTERCEPT PHARMACE ... | ORBIMED ADVISORS LLC | Director | Sell | S | 270.13 | 9,574 | 2,586,225 | 1,308,047 | 1.3 M to 1.3 M (-0.73 %) |
| Mar 25 2015 | ICPT | INTERCEPT PHARMACE ... | ORBIMED ADVISORS LLC | Director | Sell | S | 269.10 | 1,539 | 414,145 | 1,317,621 | 1.3 M to 1.3 M (-0.12 %) |
| Mar 25 2015 | ICPT | INTERCEPT PHARMACE ... | ORBIMED ADVISORS LLC | Director | Sell | S | 268.13 | 6,764 | 1,813,631 | 1,319,160 | 1.3 M to 1.3 M (-0.51 %) |
| Mar 25 2015 | ICPT | INTERCEPT PHARMACE ... | ORBIMED ADVISORS LLC | Director | Sell | S | 288.60 | 1,000 | 288,600 | 1,325,924 | 1.3 M to 1.3 M (-0.08 %) |
| Mar 25 2015 | ICPT | INTERCEPT PHARMACE ... | ORBIMED ADVISORS LLC | Director | Sell | S | 286.04 | 1,400 | 400,456 | 1,326,924 | 1.3 M to 1.3 M (-0.11 %) |
| Mar 25 2015 | ICPT | INTERCEPT PHARMACE ... | ORBIMED ADVISORS LLC | Director | Sell | S | 283.44 | 52 | 14,739 | 1,328,324 | 1.3 M to 1.3 M (0.00 %) |
| Mar 25 2015 | ICPT | INTERCEPT PHARMACE ... | ORBIMED ADVISORS LLC | Director | Sell | S | 283.29 | 1,548 | 438,533 | 1,328,376 | 1.3 M to 1.3 M (-0.12 %) |
| Mar 25 2015 | ICPT | INTERCEPT PHARMACE ... | ORBIMED ADVISORS LLC | Director | Sell | S | 282.00 | 3,500 | 987,000 | 1,329,924 | 1.3 M to 1.3 M (-0.26 %) |
| Mar 25 2015 | ICPT | INTERCEPT PHARMACE ... | ORBIMED ADVISORS LLC | Director | Sell | S | 281.01 | 6,306 | 1,772,049 | 1,333,424 | 1.3 M to 1.3 M (-0.47 %) |
| Mar 25 2015 | ICPT | INTERCEPT PHARMACE ... | ORBIMED ADVISORS LLC | Director | Sell | S | 280.00 | 9,465 | 2,650,200 | 1,339,730 | 1.3 M to 1.3 M (-0.70 %) |
| Mar 25 2015 | ICPT | INTERCEPT PHARMACE ... | ORBIMED ADVISORS LLC | Director | Sell | S | 279.00 | 3,668 | 1,023,372 | 1,349,195 | 1.4 M to 1.3 M (-0.27 %) |
| Mar 25 2015 | ICPT | INTERCEPT PHARMACE ... | ORBIMED ADVISORS LLC | Director | Sell | S | 278.00 | 14,152 | 3,934,256 | 1,352,863 | 1.4 M to 1.4 M (-1.04 %) |
| Mar 25 2015 | ICPT | INTERCEPT PHARMACE ... | ORBIMED ADVISORS LLC | Director | Sell | S | 276.96 | 8,195 | 2,269,687 | 1,367,015 | 1.4 M to 1.4 M (-0.60 %) |
| Mar 25 2015 | ICPT | INTERCEPT PHARMACE ... | ORBIMED ADVISORS LLC | Director | Sell | S | 275.95 | 37,666 | 10,393,933 | 1,375,210 | 1.4 M to 1.4 M (-2.67 %) |
| Mar 25 2015 | ICPT | INTERCEPT PHARMACE ... | ORBIMED ADVISORS LLC | Director | Sell | S | 274.86 | 3,579 | 983,724 | 1,412,876 | 1.4 M to 1.4 M (-0.25 %) |
| Mar 25 2015 | ICPT | INTERCEPT PHARMACE ... | ORBIMED ADVISORS LLC | Director | Sell | S | 273.89 | 11,869 | 3,250,800 | 1,416,455 | 1.4 M to 1.4 M (-0.83 %) |
| Mar 25 2015 | ICPT | INTERCEPT PHARMACE ... | ORBIMED ADVISORS LLC | Director | Sell | S | 272.79 | 8,638 | 2,356,360 | 1,428,324 | 1.4 M to 1.4 M (-0.60 %) |
| Mar 25 2015 | ICPT | INTERCEPT PHARMACE ... | ORBIMED ADVISORS LLC | Director | Sell | S | 271.70 | 7,764 | 2,109,479 | 1,436,962 | 1.4 M to 1.4 M (-0.54 %) |
| Mar 25 2015 | ICPT | INTERCEPT PHARMACE ... | ORBIMED ADVISORS LLC | Director | Sell | S | 270.70 | 40,598 | 10,989,879 | 1,444,726 | 1.5 M to 1.4 M (-2.73 %) |
| Mar 24 2015 | ICPT | INTERCEPT PHARMACE ... | WILLIAMS NICOLE | Director | Option Exercise | M | 9.82 | 973 | 9,557 | 4,003 | |
| Mar 24 2015 | ICPT | INTERCEPT PHARMACE ... | WILLIAMS NICOLE | Director | Sell | S | 305.36 | 973 | 297,115 | 962 | 1.9 K to 962 (-50.28 %) |
| Mar 24 2015 | ICPT | INTERCEPT PHARMACE ... | WILLIAMS NICOLE | Director | Buy | M | 9.82 | 973 | 9,557 | 1,935 | 962 to 1.9 K (+101.14 %) |
| Mar 18 2015 | ICPT | INTERCEPT PHARMACE ... | Shapiro David | CMO and EVP - Devel ... | Option Exercise | M | 10.40 | 3,500 | 36,400 | 203 | |
| Mar 18 2015 | ICPT | INTERCEPT PHARMACE ... | Shapiro David | CMO and EVP - Devel ... | Sell | S | 288.26 | 2,500 | 720,640 | 18,796 | 21.3 K to 18.8 K (-11.74 %) |
| Mar 18 2015 | ICPT | INTERCEPT PHARMACE ... | Shapiro David | CMO and EVP - Devel ... | Sell | S | 283.50 | 1,000 | 283,500 | 21,296 | 22.3 K to 21.3 K (-4.49 %) |
| Mar 18 2015 | ICPT | INTERCEPT PHARMACE ... | Shapiro David | CMO and EVP - Devel ... | Buy | M | 10.40 | 3,500 | 36,400 | 22,296 | 18.8 K to 22.3 K (+18.62 %) |
| Mar 16 2015 | ICPT | INTERCEPT PHARMACE ... | Shapiro David | CMO and EVP - Devel ... | Option Exercise | M | 8.67 | 5,000 | 43,334 | 5,971 | |
| Mar 16 2015 | ICPT | INTERCEPT PHARMACE ... | Shapiro David | CMO and EVP - Devel ... | Sell | S | 285.99 | 5,000 | 1,429,938 | 18,796 | 23.8 K to 18.8 K (-21.01 %) |
| Mar 16 2015 | ICPT | INTERCEPT PHARMACE ... | Shapiro David | CMO and EVP - Devel ... | Buy | M | 8.67 | 5,000 | 43,334 | 23,796 | 18.8 K to 23.8 K (+26.60 %) |
| Mar 12 2015 | ICPT | INTERCEPT PHARMACE ... | VEITINGER KLAUS R DR | Director | Option Exercise | M | 21.50 | 391 | 8,407 | 9,145 | |
| Mar 12 2015 | ICPT | INTERCEPT PHARMACE ... | VEITINGER KLAUS R DR | Director | Sell | S | 263.25 | 158 | 41,594 | 2,166 | 2.3 K to 2.2 K (-6.80 %) |
| Mar 12 2015 | ICPT | INTERCEPT PHARMACE ... | VEITINGER KLAUS R DR | Director | Sell | S | 261.25 | 233 | 60,871 | 2,324 | 2.6 K to 2.3 K (-9.11 %) |
| Mar 12 2015 | ICPT | INTERCEPT PHARMACE ... | VEITINGER KLAUS R DR | Director | Buy | M | 21.50 | 391 | 8,407 | 2,557 | 2.2 K to 2.6 K (+18.05 %) |